IP Library Granted Patent US 6,974,672
Granted Patent B2
US 6,974,672 · App. 10/390,191 · Granted Dec 13, 2005

Gene amplification in cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,974,672
App. No.
10/390,191
Granted
Dec 13, 2005
Kind
B2
Abstract

There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the CTSZ and CD24 genes, which are amplified colon cancer and/or ovarian cancer and/or breast cancer genes. The CTSZ and CD24 genes, their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or vaccine; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.

Claims (12)

1. A method for diagnosing a cancer in a human, comprising:

a) determining Cathepsin Z(CTSZ) gene copy number in a test biological subject from a region of the human that is suspected to be precancerous or cancerous, thereby generating data for a test gene copy number; and

b) comparing the data for the test gene copy number to data for a control gene copy number, wherein an amplification of the gene in the test biological subject relative to the control indicates the presence of a precancerous lesion or a cancer in the human.

2. The method according to claim 1 , wherein the cancer is a colon cancer, an ovarian cancer or a breast cancer.

3. The method according to claim 1 , wherein at least one of the data for the test gene copy number and the data for the control gene copy number is stored in an electronic or a paper format.

4. The method according to claim 1 , wherein the test gene copy number is determined by a hybridization- and/or an amplification-based assay.

5. The method according to claim 1 , wherein the test gene copy number is determined by ligase chain reaction (LCR).

6. The method according to claim 1 , wherein the test gene copy number is determined by polymerase chain reaction (PCR).

7. The method according to claim 1 , wherein the test gene copy number is determined by real-time quantitative RT-PCR.

8. The method according to claim 1 , wherein the test gene copy number is determined by fluorescence in situ hybridization (FISH).

9. The method according to claim 1 , wherein the test gene copy number is determined by comparative genomic hybridization (CGH).

10. The method according to claim 1 , wherein the test gene copy number is determined by microarray-based CGH.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2005
From: AMGEN SF, LLC
To: AMGEN INC.
Reel/Frame 016307/0406 →
MERGER Recorded Jun 7, 2005
From: TULARIK INC.
To: ARROW ACQUISITION, LLC
Reel/Frame 016309/0003 →
CHANGE OF NAME Recorded Jun 7, 2005
From: ARROW ACQUISITION, LLC
To: AMGEN SF, LLC
Reel/Frame 016309/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2003
From: LI. JING; POWERS, SCOTT; YANG, JIANXIN
To: TULARIK INC.
Reel/Frame 014286/0855 →